Journal of Global Infectious DiseasesOfficial Publishing of INDUSEM and OPUS 12 Foundation, Inc. Users online:507  
Print this pageEmail this pageSmall font sizeDefault font sizeIncrease font size     
Home About us Editors Ahead of Print Current Issue Archives Search Instructions Subscribe Advertise Login 
 

    Article Cited by others

SYMPOSIUM - LIESHMANIASIS

Liposomal amphotericin B and leishmaniasis: Dose and response

Sundar Shyam, Chakravarty Jaya

Year : 2010| Volume: 2| Issue : 2 | Page no: 159-166

   This article has been cited by
 
1 Vector Saliva in Vaccines for Visceral Leishmaniasis: A Brief Encounter of High Consequence?
Shaden Kamhawi,Hamide Aslan,Jesus G. Valenzuela
Frontiers in Public Health. 2014; 2
[Pubmed]  [Google Scholar] [DOI]
2 Stability and toxicity of heteroleptic organometallic Bi(v) complexes towards Leishmania major
Yih Ching Ong,Victoria L. Blair,Lukasz Kedzierski,Philip C. Andrews
Dalton Transactions. 2014; 43(34): 12904
[Pubmed]  [Google Scholar] [DOI]
3 Oral azithromycin versus its combination with miltefosine for the treatment of experimental Old World cutaneous leishmaniasis
Eglal I. Amer,Maha M. Eissa,Shereen F. Mossallam
Journal of Parasitic Diseases. 2014;
[Pubmed]  [Google Scholar] [DOI]
4 Poly(methacrylic acid) complexation of amphotericin B to treat neglected diseases
Karolina Alicja Les,Abeer H. A. Mohamed-Ahmed,Sibu Balan,Ji-won Choi,Denis Martin,Vanessa Yardley,Keith Powell,Antony Godwin,Steve Brocchini
Polymer Chemistry. 2014; 5(3): 1037
[Pubmed]  [Google Scholar] [DOI]
5 Drug repurposing and human parasitic protozoan diseases
Katherine T. Andrews,Gillian Fisher,Tina S. Skinner-Adams
International Journal for Parasitology: Drugs and Drug Resistance. 2014;
[Pubmed]  [Google Scholar] [DOI]
6 Análisis de la utilización de anfotericina B liposomal
María González Martínez,Carolina Mariño Martínez,Gema Baldominos Utrilla,María Nélida Fernández Martínez
Revista Iberoamericana de Micología. 2013;
[Pubmed]  [Google Scholar] [DOI]
7 Noncovalent Complexation of Amphotericin-B with Poly(a-glutamic acid)
Abeer H. A. Mohamed-Ahmed,Karolina A. Les,Karin Seifert,Simon L. Croft,Stephen Brocchini
Molecular Pharmaceutics. 2013; 10(3): 940
[Pubmed]  [Google Scholar] [DOI]
8 Modes of action of Leishmanicidal antimicrobial peptides
Alexandra K Marr,Bradford S McGwire,W Robert McMaster
Future Microbiology. 2012; 7(9): 1047
[Pubmed]  [Google Scholar] [DOI]
9 A pilot study comparing low-dose liposomal amphotericin B with N-methyl glucamine for the treatment of American cutaneous leishmaniasis
J.O.C. Motta,R.N.R. Sampaio
Journal of the European Academy of Dermatology and Venereology. 2012; 26(3): 331
[Pubmed]  [Google Scholar] [DOI]
10 A novel mechanism for an old drug: Amphotericin B in the treatment of visceral leishmaniasis
Amitabha Chattopadhyay,Md. Jafurulla
Biochemical and Biophysical Research Communications. 2011; 416(1-2): 7
[Pubmed]  [Google Scholar] [DOI]
11 Rare splenic complications and specific serology: decisive diagnostic tools in two cases of visceral leishmaniasis
Andrea Celestini,Federica Paglia,Orlando Dell’ Unto,Riccardo Guarisco,Claudio Puoti
Italian Journal of Medicine. 2011; 5(4): 274
[Pubmed]  [Google Scholar] [DOI]
12 Amphotericin B Membrane Action: Role for Two Types of Ion Channels in Eliciting Cell Survival and Lethal Effects
B. Eleazar Cohen
The Journal of Membrane Biology. 2010; 238(1-3): 1
[Pubmed]  [Google Scholar] [DOI]

 

Read this article
Sitemap | What's New | Feedback | Copyright and Disclaimer | Contact Us
© 2008 Journal of Global Infectious Diseases | Published by Wolters Kluwer - Medknow
Online since 10th December, 2008